Transcatheter Aortic Valve Replacement (TAVR)

Transcatheter aortic valve replacement (TAVR), or transcatheter aortic valve implantation (TAVI) in European clinical practice,  has transformed the treatment of aortic stenosis over the past two decades, offering patients who were once considered too high-risk for open heart surgery a minimally invasive route to a functioning new valve and a dramatically improved quality of life.

This guide covers everything patients need to know about the TAVR procedure — how it works, who qualifies, what recovery involves, and what the evidence says about long-term outcomes.

What Is Aortic Stenosis and Why Does It Require Treatment?

The aortic valve sits between the left ventricle and the aorta, opening with each heartbeat to allow oxygenated blood to flow out to the body and closing to prevent it from flowing back. Aortic stenosis is the progressive narrowing of this valve — most commonly caused by age-related calcium accumulation on the valve leaflets — which forces the heart to work harder to push blood through an increasingly restricted opening.

As the valve narrows, the heart muscle thickens and eventually weakens under the sustained pressure load. When aortic stenosis becomes severe, it produces a characteristic triad of symptoms: exertional chest pain, breathlessness, and episodes of dizziness or fainting — symptoms that can overlap with those of heart attack and require careful clinical differentiation. Untreated severe symptomatic aortic stenosis carries a median survival of two to three years — making valve replacement not merely a quality-of-life intervention but a life-saving one.

Historically, surgical aortic valve replacement through open heart surgery was the only available treatment. TAVR changed that equation entirely.

What Is the TAVR Procedure?

The TAVR procedure replaces the diseased aortic valve without opening the chest. A collapsible replacement valve — the TAVR valve — is crimped onto a catheter delivery system, advanced through a blood vessel to the heart, positioned precisely within the diseased native valve, and deployed by expanding a balloon or by self-expansion, depending on the valve platform used. The new valve pushes the calcified native leaflets aside and immediately begins functioning in their place.

The most common access route is transfemoral — through the femoral artery in the groin — which requires no surgical incision beyond a small arterial puncture and allows the procedure to be performed under sedation rather than general anaesthesia in many patients. Alternative access routes including transapical, transaortic, and subclavian approaches are used where femoral access is anatomically unsuitable.

The TAVR operation is performed in a cardiac catheterisation laboratory or hybrid operating theatre by a multidisciplinary heart team comprising interventional cardiologists, cardiovascular surgeons, anaesthesiologists, and imaging specialists. Precise valve positioning is guided by fluoroscopy and transoesophageal or transthoracic echocardiography throughout the procedure.

Who Qualifies for the TAVR Procedure?

Patient selection for TAVR is determined by the multidisciplinary heart team following comprehensive assessment of cardiac anatomy, surgical risk, and overall clinical status. The question of who qualifies for TAVR procedure has evolved significantly since the technique was first introduced for inoperable patients — it now encompasses a broad spectrum of surgical risk categories.

Current indications include:

• Severe symptomatic aortic stenosis in patients at high or prohibitive surgical risk — the original indication for which TAVR was developed
• Severe symptomatic aortic stenosis in intermediate surgical risk patients, where TAVR has demonstrated non-inferior outcomes to surgery in landmark trials
• Selected low surgical risk patients with severe symptomatic aortic stenosis, following evidence from the PARTNER 3 and Evolut Low Risk trials supporting TAVR in this population
• Patients with severe aortic stenosis and frailty, comorbidities, or anatomical features that make open heart surgery disproportionately risky

Anatomical suitability — assessed by cardiac CT — is a prerequisite. Adequate annular dimensions, appropriate vascular access, and the absence of anatomical features that preclude safe valve deployment must be confirmed before TAVR is offered. Patients with congenital heart disease affecting valve morphology, including bicuspid aortic valve, require particularly detailed anatomical assessment before TAVR is considered.

In cases where tissue diagnosis is required — for example, where an intracardiac mass or unusual valve pathology is identified on imaging — a biopsy may be performed as part of the pre-procedural workup before TAVR proceeds.

Outcomes of TAVR in Bicuspid Aortic Valve Disease

Bicuspid aortic valve disease — a congenital abnormality in which the aortic valve has two leaflets rather than the normal three — presents specific technical challenges for TAVR due to the asymmetric, often heavily calcified valve morphology and the associated aortic root abnormalities. Early TAVR trials excluded bicuspid anatomy, and the condition was historically considered a relative contraindication. More recent evidence has been more encouraging: outcomes of TAVR in bicuspid aortic valve disease have improved substantially with newer-generation valve systems and more experienced operators, with procedural success rates and short-term clinical outcomes approaching those seen in tricuspid anatomy at high-volume specialist centres. Patient selection and detailed pre-procedural CT planning remain critical determinants of outcome in this anatomical subgroup.

TAVR vs Open Heart Surgery

The comparison between TAVR vs open heart surgery is no longer simply a question of which is safer for the highest-risk patients — it has become a nuanced clinical decision across the full risk spectrum.

Surgical aortic valve replacement remains an excellent operation with decades of outcome data, the ability to address concomitant cardiac pathology — including coronary artery disease requiring coronary artery bypass graft — in the same procedure, and proven long-term valve durability extending beyond twenty years in many cases. TAVR offers the advantages of avoiding cardiopulmonary bypass, significantly shorter hospital stay, faster recovery, and equivalent or superior short-term survival in most risk categories studied to date.

For patients with arrhythmias identified during workup, cardiac ablation may be considered as part of the broader treatment plan before or after valve intervention. The principal remaining uncertainty with TAVR relates to very long-term valve durability — since the oldest TAVR valves have been in place for approximately fifteen years, the full lifetime performance of current-generation devices in younger patients is not yet established with the same evidence base as surgical valves.

Current practice at most high-volume centres reflects a shared decision-making model in which age, anatomical factors, patient preference, and clinical risk together determine whether TAVR or surgery is recommended — rather than risk score alone.

TAVR Recovery Time and What to Expect After the Procedure

One of the most significant advantages of TAVR over open heart surgery is the speed and ease of recovery. For most transfemoral TAVR patients, the timeline looks broadly as follows:

• Hospital stay — typically two to five days, compared to five to seven or more days following open surgical replacement
• Return to light daily activity — most patients are mobile and self-caring within days of the procedure
• Return to normal activity — the majority of patients resume their usual routine within two to four weeks
• Cardiac rehabilitation — a structured exercise and education programme that optimises recovery and long-term outcomes, typically beginning within four to six weeks

The recovery experience is substantially gentler than open surgery because there is no sternotomy — no division and subsequent healing of the breastbone — and no prolonged period on cardiopulmonary bypass. Patients who were severely limited by breathlessness or fatigue before TAVR frequently notice an improvement in symptoms within days of the procedure as the newly functioning valve immediately relieves the pressure load on the heart.

Fatigue After TAVR Procedure

Fatigue after TAVR procedure is common and expected in the weeks following the operation, and patients should be reassured that it does not indicate a complication. The body requires time to adjust to the restored cardiac output, and the combination of hospitalisation, procedural stress, and pre-existing deconditioning — common in elderly patients with severe aortic stenosis — all contribute to a period of tiredness that typically resolves progressively over four to eight weeks. Cardiac rehabilitation, adequate nutrition, and gradual increases in physical activity all support recovery and shorten the fatigue period.

Side Effects After TAVR Surgery

The most clinically important side effects after TAVR surgery include:

• Conduction abnormalities — new left bundle branch block or complete heart block requiring permanent pacemaker implantation, occurring in five to twenty-five percent of cases depending on the valve platform used
• Vascular access complications — bleeding or injury at the femoral artery access site, managed by the procedural team at the time of the procedure in most cases
• Paravalvular leak — mild regurgitation around the outside of the deployed valve, present to some degree in a proportion of patients and associated with worse outcomes when more than mild
• Stroke — a risk of approximately two to three percent in the periprocedural period, mitigated by cerebral embolic protection devices at centres that use them routinely
• Acute kidney injury — particularly in patients with pre-existing renal impairment

The overall safety profile of current-generation TAVR devices is excellent, and serious complications have become less frequent as operator experience and device technology have matured.

How Long Does a TAVR Last?

How long does a TAVR last is one of the most frequently asked questions by patients considering the procedure — and one to which the honest answer remains partially incomplete. Current evidence suggests that newer-generation TAVR valves perform well for at least ten to fifteen years in the majority of patients, with structural valve deterioration rates at ten years comparable to those seen with surgical bioprosthetic valves over similar timeframes. Longer-term data are still accumulating, and the performance of the most current device generations over a twenty-year horizon will not be known for some years yet.

For older patients — the majority of the current TAVR population — valve durability is unlikely to be the limiting factor in clinical outcomes. For younger patients receiving TAVR, the possibility of future valve-in-valve TAVR to treat a deteriorated first implant is a well-established and increasingly used strategy that extends the useful life of the transcatheter approach beyond the lifespan of the first device.

Life Expectancy After TAVR Procedure

Life expectancy after TAVR procedure depends primarily on the patient's age, overall health, and the severity of any comorbidities — not on the procedure itself. In patients with severe symptomatic aortic stenosis, TAVR restores life expectancy toward age-matched norms, with survival curves in low and intermediate risk trials closely tracking those of surgical patients at two to five years. In high-risk and inoperable patients, TAVR significantly extends survival compared to medical therapy alone, even if overall life expectancy remains influenced by the burden of underlying comorbidity. The procedure is not a cure for all cardiovascular disease — but in appropriately selected patients, it is a highly effective intervention that meaningfully extends both life and quality of life.

TAVR and Cardiac Surgery at Medical Park Hospitals

Medical Park Hospitals delivers TAVR and the full spectrum of structural heart disease interventions through dedicated heart teams in interventional cardiology and cardiac surgery, supported by hybrid operating theatre infrastructure and advanced cardiac imaging capability. For international patients seeking TAVR in Turkey, Medical Park combines internationally accredited clinical standards with treatment costs substantially below those of Western Europe or North America — and with waiting times that allow time-sensitive interventions to be scheduled without the delays that publicly funded systems frequently impose.